2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 29

A Novel CD27^(-) B-Cell Subset Identified Based On Intracellular Characteristics Is Expanded In SLE
Abstract Number: 2779

A Novel Evidence-Based Detection Of Undiagnosed Spondyloarthritis In Patients Presenting With Acute Anterior Uveitis: The DUET (Dublin Uveitis Evaluation Tool) Algorithm
Abstract Number: 2642

A Novel Genetic Basis For Systemic Vasculitis: Polyarteritis Nodosa Caused By Recessive Mutations In An Immune-Related Gene
Abstract Number: 1325

A Novel Index To Identify Interstitial Lung Disease In Rheumatoid Arthritis Patients
Abstract Number: 1477

A Novel Method Predicting Good Response Using Only Background Clinical Data In RA Patients Treated With Infliximab
Abstract Number: 1169

A Novel Pro-Inflammatory Signaling Pathway Regulated By Follistatin-Like Protein 1
Abstract Number: 509

A Novel Screening Tool Indicative Of Primary Sjogren’s Syndrome Versus Sicca Symptoms
Abstract Number: 1968

A Novel, Feasible and Reliable Method Of Radiographic Scoring Of Rheumatoid Arthritis
Abstract Number: 839

A Paradigm Change for Treatment Strategies for Fibromyalgia Syndrome Reflected By Recommendations of Recent Evidence-Based Interdisciplinary Guidelines Developed Independently in Three Countries
Abstract Number: L3

A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
Abstract Number: 1608

A Phase I Single-Dose Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus
Abstract Number: 1734

A Phase Ib Clinical Trial With Dekavil (F8-IL10), An Immunoregulatory ‘Armed Antibody’ For The Treatment Of Rheumatoid Arthritis, Used In Combination With Methotrexate
Abstract Number: 1735

A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate
Abstract Number: 2177

A Pilot Study Of Juvenile Localized Scleroderma (jLS) Consensus Treatment Plans
Abstract Number: 1277

A Pilot Study Of Young Adults With Juvenile Dermatomyositis With Decreased Nailfold Capillary End Row Loops: Brachial Artery Reactivity and Oxidized Lipids

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].